On Tuesday, Pro-Dex got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Pro-Dex is now out of buy range after clearing the 22.99 entry in a cup without handle. Note that it is a thinly traded stock, with average daily dollar volume under $8 million.
Discover The 3 Keys To Successful Stock Investing
The stock sports an 86 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 86% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported 336% EPS growth for Q2. Sales growth increased 33%, up from 25% in the prior report. That marks one quarter of accelerating revenue growth.
Pro-Dex holds the No. 3 rank among its peers in the Medical-Products industry group. Boston Scientific is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
